Cambium bio limited

Index
Globenewswire

Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease

Globenewswire

Cambium Bio Successfully Closes A$3.0M Financing Round